Cellectar Biosciences, Inc. Resources

Patients News & Media Investors Contact

Cellectar Biosciences, Inc.

  • Home
  • About
    • Overview
    • Partnerships
    • Management Team
    • Board of Directors
  • Platform
    • Overview
    • Posters & Publications
  • Product Pipeline
    • Overview
    • Iopofosine
  • Clinical Studies
    • Overview
    • Waldenstrom’s Macroglobulinemia Pivotal Study Recruiting
    • Relapsed or Refractory Select B-Cell Malignancies Clinical Study Recruiting
    • Children With Relapsed or Refractory Malignant Cancer Clinical Study Recruiting
  • Patients
  • News & Media
  • Investors
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Presentations
  • Events

Cellectar Biosciences Announces $10.0 Million Financing

May 16, 2019

CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma

May 15, 2019

Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma

May 13, 2019

Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update

May 6, 2019

FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients

Mar 19, 2019

Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update

Feb 26, 2019

Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131

Feb 25, 2019

Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference

Feb 5, 2019

Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference

Jan 23, 2019

Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

Jan 7, 2019
    • 1...
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • 14
    • ...30
    © 2023 Cellectar Biosciences, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Q&A